CLINICAL TRIALS PROFILE FOR INDACATEROL MALEATE
✉ Email this page to a colleague
All Clinical Trials for Indacaterol Maleate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00396604 ↗ | Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD) | Completed | Novartis | Phase 2/Phase 3 | 2006-10-01 | The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD. All patients will receive 1 day of treatment with each of the following: indacaterol 150 µg, once- indacaterol 300 µg, indacaterol 600 µg, placebo, and formoterol. Each treatment day will be followed by a washout-period of 1 week. |
| NCT00403637 ↗ | Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma | Completed | Novartis | Phase 2/Phase 3 | 2006-11-01 | The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with persistent asthma. All patients will receive 1 day of treatment with each of the following: indacaterol 150 µg, indacaterol 300 µg, indacaterol 600 µg, placebo, and formoterol. Each treatment day will be followed by a washout-period of 1 week |
| NCT00556673 ↗ | Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2007-10-01 | This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500 μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent asthma. |
| NCT00556673 ↗ | Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma | Completed | Novartis | Phase 2 | 2007-10-01 | This study is designed to evaluate the bronchodilatory efficacy of indacaterol maleate 500 μg/mometasone furoate 400 μg via the Twisthaler® device in adult patients with persistent asthma. |
| NCT00605306 ↗ | Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2008-01-01 | This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma. |
| NCT00605306 ↗ | Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma | Completed | Novartis | Phase 2 | 2008-01-01 | This study will investigate the safety and tolerability of indacaterol maleate/mometasone furoate via the Twisthaler device after 14 days treatment in patients with mild to moderate asthma. |
| NCT00624702 ↗ | Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent Asthma | Completed | Novartis | Phase 1 | 2008-02-01 | This study will explore information on whether changing the salt formulation of indacaterol affects the incidence of post-inhalation cough. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Indacaterol Maleate
Condition Name
Clinical Trial Locations for Indacaterol Maleate
Trials by Country
Clinical Trial Progress for Indacaterol Maleate
Clinical Trial Phase
Clinical Trial Sponsors for Indacaterol Maleate
Sponsor Name
